Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation
Open accessThe DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.
Abstract
Gemcitabine combined with cisplatin is the first-line chemotherapy for advanced cholangiocarcinoma, but drug resistance remains a challenge, leading to unsatisfactory therapeutic effect. Here, we elucidate the possibility of chemotherapy regimens sensitized by inhibiting succinylation in patients with cholangiocarcinoma from the perspective of post-translational modification. Our omics analysis reveals that succinylation of PDHA1 lysine 83, a key enzyme in the tricarboxylic acid cycle, alters PDH enzyme activity, modulates metabolic flux, and leads to alpha-ketoglutaric acid accumulation in the tumor microenvironment. This process activates the OXGR1 receptor on macrophages, triggering MAPK signaling and inhibiting MHC-II antigen presentation, which promotes immune escape and tumor progression. Moreover, we show that inhibiting PDHA1 succinylation with CPI-613 enhances the efficacy of gemcitabine and cisplatin. Targeting PDHA1 succinylation may be a promising strategy to improve treatment outcomes in cholangiocarcinoma and warrants further clinical exploration. Succinylation, a posttranslational modification on lysine residues, is involved in tumor progression. Here, authors show that PDHA1 K83 succinylation is involved in cholangiocarcinoma tumorigenesis through regulation of macrophage antigen presentation in the tumor microenvironment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, high PDHA1 succinylation is associated with poor survival, and in mice, CD8+ T-cell depletion reversed the protumoral effects of PDHA1 succinylation [218].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings
Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00203 · Cited by 7,546
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“A functional TCA cycle depends on the continuous and balanced replenishment of its key metabolites, many of which exit the mitochondria to act as precursors for biosynthesis or to participate in signaling pathways 37,39 .”
The Gene Ontology (GO) database and informatics resource
Gene Ontology Consortium (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh036 · Cited by 4,579
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
A guide to immunometabolism for immunologists
O'Neill, L. A. J., Kishton, R. J., & Rathmell, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.70 · Cited by 3,315
The Human Serum Metabolome (HUSERMET) Consortium, Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., Brown, M., Knowles, J. D., Halsall, A., et al. (2011) · Nature Protocols · doi:10.1038/nprot.2011.335 · Cited by 3,294
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“Endogenous metabolites are implicated in modulating cellular processes, such as immune homeostasis and tumor development 20,21 .”
RSeQC: quality control of RNA-seq experiments
Wang, L., Wang, S., & Li, W. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts356 · Cited by 2,788
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740 · cited 2×
“Metabolic reprogramming, a hallmark of cancer, is intricately linkedtopost-translationalmodi fi cations(PTMs) 5,6 .”
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Research works printed but not linked: 1
- Wu, J. Y. et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol. Cell. 77, 213–227.e5 (2020). · DOI · Paper page
Cited by
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Metabolic reprogramming in cancer: signaling pathways and therapeutic targets
Dong, S., & Lei, X. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02582-0 · Cited by 40
Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance
Zhu, Y., Yan, W., Tong, L., Yang, J., Ge, S., Fan, J., Jia, R., & Wen, X. (2025) · MedComm · doi:10.1002/mco2.70358 · Cited by 38
Hu, S., Heng, H., Yang, F., Wang, M., Liu, G., Xiang, Y., & Miao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1735873 · Cited by 33
Cancer drug response and resistance: molecular mechanisms and combating strategies
Cheng, X., Xu, M., Wei, J., & Cao, C. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02924-w · Cited by 15
Metadata
- Authors
- Zhang, N., Sun, L., Zhou, S., Ji, C., Cui, T., Chu, Q., Ye, J., Liang, S., Ma, K., Liu, Y., Li, X., Guo, X., Zhang, W., Gu, X., Cheng, C., Zha, Q., Tao, S., Zhang, Y., Chu, J., Wu, C., Zhang, Y., Wang, J., Liu, Y., & Liu, L.
- Affiliations
- First Affiliated Hospital of Harbin Medical University (CN)
- University of Science and Technology of China (CN)
- Sun Yat-sen University Cancer Center (CN)
- Jining First People's Hospital (CN)
- Harbin Medical University (CN)
- Corresponding author
- Liu, Yufeng
- Wang, Jiabei
- ORCID
- Venue
- Nature Communications
- Published
- 2025-04-03
- Volume
- 16
- Issue
- 1
- Pages
- 3177-3177
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11968997
- OpenAlex
- W4409149833
- Cited by
- 34
- References
- 81
- Citations by year
- 2026: 22 · 2025: 12
- FWCI
- 31.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (No.82102705, No. U19A2008, No. U19A2008, No.82272787, No.82373232, No.82473189, No.82303259)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- cholangiocarcinoma, PDHA1, lysine succinylation, macrophage antigen presentation, MHC class II, MAPK signaling, tumor immune evasion, CPI-613, gemcitabine, cisplatin, drug resistance, TCA cycle, tumor microenvironment, post-translational modification
- MeSH terms
- Gemcitabine, Animals, Bile Duct Neoplasms, Cisplatin, Deoxycytidine, Female, Humans, Ketoglutaric Acids, Macrophages, Male, Protein Processing, Post-Translational, Antigen Presentation, Cholangiocarcinoma, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. https://app.cochat.ai/papers/10.1038/s41467-025-58429-7
- The paper
- Zhang, N., Sun, L., Zhou, S., Ji, C., Cui, T., Chu, Q., Ye, J., Liang, S., Ma, K., Liu, Y., Li, X., Guo, X., Zhang, W., Gu, X., Cheng, C., Zha, Q., Tao, S., Zhang, Y., Chu, J., . . . Liu, L. (2025). Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. Nature Communications. https://doi.org/10.1038/s41467-025-58429-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.